See more : Parkson Holdings Berhad (5657.KL) Income Statement Analysis – Financial Results
Complete financial analysis of Revelation Biosciences, Inc. (REVB) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Revelation Biosciences, Inc., a leading company in the Biotechnology industry within the Healthcare sector.
- Thunderbird Entertainment Group Inc. (THBRF) Income Statement Analysis – Financial Results
- The Western India Plywoods Limited (WIPL.NS) Income Statement Analysis – Financial Results
- hyungji Elite Co., Ltd. (093240.KS) Income Statement Analysis – Financial Results
- Raj Rayon Industries Limited (RAJRAYON.NS) Income Statement Analysis – Financial Results
- WK Kellogg Co (KLG) Income Statement Analysis – Financial Results
Revelation Biosciences, Inc. (REVB)
About Revelation Biosciences, Inc.
Revelation Biosciences, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of immune system therapeutics and diagnostics. The company engages in developing therapeutic product candidates, including REVTx-99b that is in a Phase Ib clinical trial for the prevention or treatment of chronic nasal congestion and allergic rhinitis; and REVTx-200, a nonclinical stage product for intranasal therapy. It is also involved in developing REVTx-300, a non-clinical stage product that is being developed as a potential therapy for the treatment of chronic organ disease, including chronic kidney disease and non-alcoholic steatohepatitis; and REVDx-501, a rapid test kit, which is a point of care in vitro diagnostic test that has the potential to detect respiratory viral infections, such as SARS-CoV-2, Influenza A, Influenza B, parainfluenza, or respiratory syncytial virus. The company was founded in 2020 and is based in San Diego, California.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 |
|---|---|---|---|---|---|
| Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Cost of Revenue | 25.05K | 40.01K | 69.17K | 0.00 | 0.00 |
| Gross Profit | -25.05K | -40.01K | -69.17K | 0.00 | 0.00 |
| Gross Profit Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Research & Development | 4.15M | 5.38M | 6.91M | 2.56M | 0.00 |
| General & Administrative | 4.51M | 5.49M | 5.04M | 1.23M | 0.00 |
| Selling & Marketing | 0.00 | 0.00 | 0.00 | 144.26K | 0.00 |
| SG&A | 4.51M | 5.49M | 5.04M | 145.49K | 3.64K |
| Other Expenses | 0.00 | 34.96K | -36.35K | 0.00 | 0.00 |
| Operating Expenses | 8.66M | 10.86M | 11.95M | 145.49K | 3.64K |
| Cost & Expenses | 8.66M | 10.86M | 11.95M | 145.49K | 3.64K |
| Interest Income | 0.00 | 0.00 | 0.00 | 10.92K | 0.00 |
| Interest Expense | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Depreciation & Amortization | 25.05K | 40.01K | 69.17K | 3.80M | 171.86K |
| EBITDA | -95.21K | -10.84M | -11.93M | -145.49K | -3.64K |
| EBITDA Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Operating Income | -8.66M | -10.86M | -11.95M | -145.49K | -3.64K |
| Operating Income Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Total Other Income/Expenses | 8.54M | 34.96K | -36.35K | -1.49M | 2.00 |
| Income Before Tax | -120.25K | -10.83M | -11.99M | -1.63M | -3.64K |
| Income Before Tax Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Income Tax Expense | 0.00 | -34.96K | -219.78K | -3.80K | -171.86K |
| Net Income | -120.25K | -10.79M | -11.99M | -1.63M | -3.64K |
| Net Income Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| EPS | -0.53 | -600.77 | -1.28K | -188.18 | -0.42 |
| EPS Diluted | -0.53 | -600.77 | -1.28K | -188.18 | -0.42 |
| Weighted Avg Shares Out | 228.00K | 17.97K | 9.40K | 8.66K | 8.66K |
| Weighted Avg Shares Out (Dil) | 228.64K | 17.97K | 9.40K | 8.66K | 8.66K |
Revelation Biosciences Inc. Gives Oral Presentation at Advances in Critical Care Nephrology (AKI & CRRT 2024)
Revelation Biosciences Inc. Receives Invitation to Give an Oral Presentation at The 29th International Conference on Advances in Critical Care Nephrology (AKI & CRRT 2024)
Top 5 Health Care Stocks That Are Preparing To Pump In February - CNS Pharma (NASDAQ:CNSP), Biolase (NASDAQ:BIOL)
Revelation Biosciences Inc. Announces Closing of $6.2 Million Public Offering
Why Is Revelation Biosciences (REVB) Stock Down 62% Today?
Revelation Biosciences Inc. Announces Pricing of $6.2 Million Public Offering
Revelation Biosciences Inc. to Present at The International Conference on Advances in Critical Care Nephrology (AKI & CRRT 2024)
Why Is Revelation Biosciences (REVB) Stock Up 61% Today?
Revelation Biosciences Inc. Announces 1-for-30 Reverse Stock Split Effective January 25, 2024
Revelation Biosciences, Inc. Announces Financial Results for the Three and Nine Months Ended September 30, 2023
Source: https://incomestatements.info
Category: Stock Reports